

Incidence, risk factors, and clinical outcomes of placental abruption in a tertiary hospital in Hong Kong: a retrospective case-control study

Jade Wing Ngan SHEK, BMedSci, MBChB, MRCOG

Po Lam SO, MBBS (HK), MMedSc (Genetic Counselling), MSc (Medical Genetics), FHKCOG, FHKAM (O&G)

Lee Ting KWONG, MBBS (HK), FHKCOG, FHKAM (O&G)

Sai Fun WONG, MBBS (HK), FRCOG, FHKCOG, FHKAM (O&G)

Department of Obstetrics and Gynaecology, Tuen Mun Hospital, Hong Kong

Introduction: This study aims to identify risk factors for placental abruption and evaluate maternal and fetal outcomes of patients with placental abruption in a tertiary hospital in Hong Kong.

Methods: Medical records of patients with placental abruption treated at the Tuen Mun Hospital between January 2017 and December 2021 were retrospectively reviewed. Data retrieved included patient demographics, alcohol/substance abuse and smoking status, obstetric history, antenatal characteristics, body mass index at first antenatal visit, clinical presentation, intrapartum events, complications, and maternal and perinatal outcomes. Each patient was matched with a control who delivered just before the patient.

Results: Of 22990 deliveries and 23230 live births, there were 86 placental abruption cases; the incidence was 0.37%. After adjusting for confounders, the risk factor for placental abruption was a history of antepartum haemorrhage. Compared with controls, patients with placental abruption had higher rates of caesarean sections (91.9% vs 23.3%, $p<0.001$), postpartum haemorrhage (62.8% vs 15.1%, $p<0.001$), uterine atony (31.4% vs 3.5%, $p<0.001$), blood transfusion (25.6% vs 3.5%, $p<0.001$), and disseminated intravascular coagulopathy (7.0% vs 0%, $p=0.029$). Compared with controls, neonates complicated with placental abruption had lower Apgar score at 1 minute (7 vs 8, $p<0.001$), higher preterm birth rate (64.0% vs 9.3%, $p<0.001$), lower birth weight (2296.4 g vs 3088.8 g, $p<0.001$), and more perinatal morbidities. Patients with a Couvelaire uterus had higher rates of uterine atony (56.3% vs 27.0%, $p=0.026$), postpartum haemorrhage (93.8% vs 61.9%, $p=0.014$), disseminated intravascular coagulopathy (25.0% vs 3.2%, $p=0.014$), blood transfusion (68.8% vs 17.5%, $p<0.001$), and secondary intervention (25.0% vs 1.6%, $p=0.005$). Neonates born from patients with a Couvelaire uterus had higher rates of acidosis (umbilical cord blood pH <7.1) [53.3% vs 5.8%, $p<0.001$], lower Apgar score at 1 minute (25.0% vs 4.8%, $p=0.028$), and hypoxic-ischaemic encephalopathy (12.5% vs 0%, $p=0.039$).

Conclusion: Clinicians should be vigilant for placental abruption in patients with antepartum haemorrhage, especially in high-risk patients with a history of placental abruption, hypertension, or pre-eclampsia. Early and consistent antenatal care is imperative to identify those with risk factors. Proper education and timely preventive management should be provided to improve maternal and fetal outcomes.

Keywords: *Abruptio placentae; Risk factors*

Introduction

Placental abruption is defined as premature separation of the placenta from the decidua at or after 20 weeks of gestation and can result in maternal and fetal morbidity and mortality. Its incidence is higher in Canada and the United States and lower in Norway, Spain, Finland, Sweden, the Netherlands, and Denmark¹. The overall incidence is approximately 3 to 10 per 1000 births^{1,2}. Clinical presentation of placental abruption includes painful vaginal bleeding with uterine contraction and hypertonicity and a non-reassuring fetal heart rate pattern³. Progression of placental abruption can be rapid, especially in cases of severe abruption. Maternal complications include haemorrhagic shock, coagulopathy and disseminated intravascular coagulation, uterine rupture, renal failure,

and ischaemic necrosis of distal organs^{4,5}. Neonatal complications include death and neurodevelopmental issues^{4,6}.

There are no reliable diagnostic tests or markers to predict or prevent the occurrence of placental abruption. Its risk factors include advanced maternal age, multiparity, smoking, cocaine and drug use, pre-eclampsia, chronic hypertension, premature rupture of membranes, trauma, polyhydramnios, structural uterine anomalies, and a history of placental abruption⁷⁻¹⁰. This study aims to identify risk factors for placental abruption and evaluate maternal and

Correspondence to: Dr Jade Wing Ngan SHEK

Email: jadeshek@gmail.com

fetal outcomes of patients with placental abruption in a tertiary hospital in Hong Kong.

Materials and methods

This study was approved by the New Territories West Cluster Research Ethics Committee (reference: NTWC/REC/22071). Medical records of patients with placental abruption treated at the Tuen Mun Hospital between January 2017 and December 2021 were identified using the International Classification of Diseases codes. Tuen Mun Hospital is a public hospital in Hong Kong handling around 5000 live births per year. Data retrieved included patient demographics, alcohol/substance abuse and smoking status, obstetric history, antenatal characteristics, body mass index at first antenatal visit, clinical presentation, intrapartum events, complications, and maternal and perinatal outcomes. Each patient was matched with a control who delivered just before the patient.

The diagnostic criteria for placental abruption were: (1) presentation of signs of painful vaginal bleeding and at least one of the following: non-reassuring fetal status, severe abdominal pain, tetanic uterine contractions, and uterine hypertonicity; (2) a freshly delivered placenta showing clinically significant retroplacental bleeding or clots; and (3) a confirmation on prenatal ultrasound. Patients often had a combination of these diagnostic criteria.

Data analysis was performed using SPSS (Windows version 26; IBM Corp, Armonk [NY], United States). A *p* value of <0.05 was considered statistically significant. The case and control groups were compared using the Student's *t* test and Mann-Whitney *U* test for continuous variables and the Chi-squared test or Fisher's exact test for categorical variables. Multivariate logistic regression analysis was used to determine risk factors for placental abruption. Subgroup analysis was performed to determine association of Couvelaire uterus with maternal and fetal outcomes.

Results

Of 22990 deliveries and 23230 live births in Tuen Mun Hospital between 2017 and 2021, there were 86 placental abruption cases; the incidence was 0.37%. The most common symptom of placental abruption was a combination of vaginal bleeding and abdominal pain (38.4%), followed by a combination of vaginal bleeding, abdominal pain, and uterine hypertonicity (24.4%) and vaginal bleeding alone (19.8%) [Table 1]. The most common clinical presentation of placental abruption was retroplacental clot during delivery (96.5%), followed by

blood-stained amniotic fluid during delivery (39.5%), a non-reassuring fetal heart rate pattern (38.4%), retroplacental clot on ultrasound (20.9%), and a Couvelaire uterus during caesarean section (18.6%).

As shown in Table 2, the case and control groups were comparable in terms of maternal age (32.4 vs 30.9 years, *p*=0.052) and the percentage of advanced maternal age (≥ 35 years) [34.9% vs 22.1%, *p*=0.063]. Compared with controls, patients with placental abruption had higher rates of pre-eclampsia (11.6% vs 3.5%, *p*=0.043), preterm prelabour rupture of membranes (16.3% vs 3.5%, *p*=0.005), a history of antepartum haemorrhage (20.9% vs 7.0%, *p*=0.008), and use of aspirin during the antenatal period (10.5% vs 0%, *p*=0.003). However, after adjusting for confounders, only a history of antepartum haemorrhage remained significant (*p*=0.013, Table 3).

Compared with controls, patients with placental abruption had higher rates of caesarean section (91.9% vs 23.3%, *p*<0.001), caesarean section for non-reassuring fetal heart rate (33.7% vs 7%, *p*<0.001), postpartum haemorrhage (blood loss ≥ 500 ml: 62.8% vs 15.1%, *p*<0.001; blood loss ≥ 1000 ml: 31.4% vs 3.5%, *p*<0.001), uterine atony (31.4% vs 3.5%, *p*<0.001), blood transfusion (25.6% vs 3.5%, *p*<0.001), disseminated intravascular coagulation (7.0% vs 0%, *p*=0.029), and prolonged hospital stay (>4 days) [30.2% vs 15.1%, *p*=0.018], and longer length of hospital stay (median, 4 vs 3 days, *p*<0.001) [Table 4]. Treatment performed for severe postpartum haemorrhage included compression sutures (*n*=4), bilateral uterine artery ligation (*n*=1), and hysterectomy (*n*=1).

As shown in Table 5, of 89 neonates (three sets of twins) in the placental abruption group, one was stillbirth. Compared with controls, neonates born from patients with placental abruption had higher rates of premature birth (before 37 weeks: 64.0% vs 9.3%, *p*<0.001; before 34 weeks: 37.1% vs 2.3%, *p*<0.001; and before 28 weeks: 11.2% vs 0%, *p*=0.002), lower birth weight (2296.4 g vs 3088.8 g, *p*<0.001), lower median Apgar score at 1 minute (7 vs 8, *p*<0.001), and higher rates of resuscitation care (18.2% vs 0%, *p*<0.001), mechanical ventilation (25.0% vs 1.2%, *p*<0.001), admission to neonatal intensive care unit (47.7% vs 1.2%, *p*<0.001), inotropes for management of haemodynamic instability (12.5% vs 0%, *p*=0.001), and blood transfusion (17.0% vs 0%, *p*<0.001). Neonates born from patients with placental abruption had higher complication rates in terms of respiratory distress syndrome (39.8% vs 0%, *p*<0.001), apnoea of prematurity (25.0% vs 0%, *p*<0.001), intraventricular haemorrhage (8.0% vs 0%,

Table 1. Symptoms, clinical presentations, and diagnostic criteria of placental abruption

| | Patients with placental abruption (n=86)* |
|--|--|
| Symptom | |
| Vaginal bleeding alone | 17 (19.8) |
| Abdominal pain alone | 7 (8.1) |
| Uterine hypertonicity alone | 1 (1.2) |
| Vaginal bleeding and abdominal pain | 33 (38.4) |
| Abdominal pain and uterine hypertonicity | 1 (1.2) |
| Vaginal bleeding and uterine hypertonicity | 6 (7.0) |
| Vaginal bleeding, abdominal pain and uterine hypertonicity | 21 (24.4) |
| Clinical presentation | |
| Non-reassuring fetal heart rate patterns | 33 (38.4) |
| Retroplacental blood clot by ultrasound | 18 (20.9) |
| Blood-stained amniotic fluid during delivery | 34 (39.5) |
| Retroplacental clot/haemorrhage during delivery | 83 (96.5) |
| Couvellaire uterus during caesarean section | 16 (18.6) |
| Diagnostic criteria | |
| Retroplacental clots/haemorrhage | 43 (50.0) |
| Ultrasound diagnosis | 1 (1.2) |
| Ultrasound diagnosis and retroplacental clots/haemorrhage | 12 (14.0) |
| Painful vaginal bleeding, uterine hypertonicity and non-reassuring fetal heart rate patterns | 1 (1.2) |
| Painful vaginal bleeding, uterine hypertonicity and retroplacental clots/haemorrhage | 7 (8.1) |
| Painful vaginal bleeding, uterine hypertonicity and ultrasound diagnosis | 1 (1.2) |
| Painful vaginal bleeding, uterine hypertonicity, non-reassuring fetal heart rate patterns and retroplacental clots/haemorrhage | 8 (9.3) |
| Painful vaginal bleeding, uterine hypertonicity, ultrasound diagnosis, non-reassuring fetal heart rate patterns and retroplacental clots/haemorrhage | 2 (2.3) |
| Painful vaginal bleeding, uterine hypertonicity, ultrasound diagnosis and retroplacental clots/haemorrhage | 2 (2.3) |
| Painful vaginal bleeding, non-reassuring fetal heart rate patterns and retroplacental clots/haemorrhage | 9 (10.5) |

* Data are presented as No. (%) of patients

$p=0.014$), chronic lung disease (8.0% vs 0%, $p=0.014$), retinopathy of prematurity (8.0% vs 0%, $p=0.014$), patent ductus arteriosus (12.5% vs 0%, $p=0.001$), neonatal hypoglycaemia (13.6% vs 3.5%, $p=0.017$), neonatal sepsis (11.4% vs 2.3%, $p=0.019$), and increased neonatal hospital stay (median, 7 vs 2 days, $p<0.001$). There were three (3.4%) early neonatal deaths because of prematurity in the placental abruption group but none in the control group.

15 of the patients had 17 subsequent pregnancies delivered beyond 24 weeks. Three of them had placental abruption; the incidence increased to 17.6% among women with a history of abruption. These three cases were not

delivered in our hospital and therefore not included in our cohort.

16 of 79 patients were found to have a Couvellaire uterus intraoperatively by the operating surgeon through visual inspection. All four patients who needed secondary intervention for postpartum haemorrhage underwent compression sutures. Compared with patients without a Couvellaire uterus, patients with a Couvellaire uterus had higher rates of uterine atony (56.3% vs 27.0%, $p=0.026$), postpartum haemorrhage (93.8% vs 61.9%, $p=0.014$), disseminated intravascular coagulation (25.0% vs 3.2%, $p=0.014$), blood transfusion (68.8% vs 17.5%, $p<0.001$),

Table 2. Characteristics of patients with placental abruption and controls

| Characteristic | Patients with placental abruption (n=86)* | Controls (n=86)* | p Value |
|--|---|------------------|---------|
| Maternal age, y | 32.4±5.0 | 30.9±5.4 | 0.052 |
| Maternal age ≥35 y | 30 (34.9) | 19 (22.1) | 0.063 |
| Maternal age <20 y | 1 (1.2) | 1 (1.2) | >0.99 |
| Body mass index, kg/m ² | 22.7 (5) | 22.6 (5) | 0.930 |
| Maternal ethnicity | | | 0.496 |
| Chinese | 80 (93.0) | 83 (96.5) | |
| South-Asian | 6 (7.0) | 3 (3.5) | |
| Tobacco use | 6 (7.0) | 3 (3.5) | 0.496 |
| Alcohol use | 2 (2.3) | 3 (3.5) | >0.99 |
| Drug abuser | 1 (1.2) | 1 (1.2) | >0.99 |
| Educational level | | | 0.426 |
| Tertiary or above | 33 (38.4) | 28 (32.6) | |
| Below tertiary | 53 (61.6) | 58 (67.4) | |
| Unmarried | 12 (14.0) | 17 (19.8) | 0.309 |
| Gravidity | 2 (2) | 2 (2) | 0.266 |
| Parity | 1 (1) | 1 (1) | 0.594 |
| Parity ≥3 | 6 (7.0) | 4 (4.7) | 0.515 |
| Nulliparity | 35 (40.7) | 40 (46.5) | 0.442 |
| History of miscarriage/stillbirth | 18 (20.9) | 9 (10.5) | 0.059 |
| History of termination of pregnancy | 18 (20.9) | 21 (24.4) | 0.585 |
| History of caesarean section | 21 (24.4) | 11 (12.8) | 0.050 |
| History of placental abruption | 4 (4.7) | 0 | 0.121 |
| Assisted conception | 6 (7.0) | 2 (2.3) | 0.277 |
| Twin pregnancy | 3 (3.5) | 0 | 0.246 |
| No antenatal care | 0 | 3 (3.5) | 0.246 |
| Hypertensive disorders | 12 (14.0) | 5 (5.8) | 0.074 |
| Chronic hypertension | 5 (5.8) | 1 (1.2) | 0.210 |
| Pregnancy induced hypertension | 4 (4.7) | 3 (3.5) | >0.99 |
| Pre-eclampsia | 10 (11.6) | 3 (3.5) | 0.043 |
| Diabetes mellitus in pregnancy | 13 (15.1) | 9 (10.5) | 0.361 |
| Pre-existing diabetes mellitus | 3 (3.5) | 0 | 0.246 |
| Gestational diabetes mellitus | 10 (11.6) | 9 (10.5) | 0.808 |
| Preterm premature rupture of membranes | 14 (16.3) | 3 (3.5) | 0.005 |
| Polyhydramnios | 1 (1.2) | 0 | >0.99 |
| Oligohydramnios | 1 (1.2) | 2 (2.3) | >0.99 |
| Uterine anomaly | 1 (1.2) | 0 | >0.99 |
| Placental praevia | 5 (5.8) | 0 | 0.059 |
| History of antepartum haemorrhage | 18 (20.9) | 6 (7.0) | 0.008 |
| History of abdominal trauma | 1 (1.2) | 0 | >0.99 |
| Use of aspirin | 9 (10.5) | 0 | 0.003 |
| Anaemia | 3 (3.5) | 4 (4.7) | >0.99 |

* Data are presented as mean ± standard deviation, median (interquartile range), or No. (%) of participants

Table 3. Risk factors for placental abruption

| Variable | Adjusted odds ratio (95% confidence interval) | p Value |
|--|--|---------|
| History of antepartum haemorrhage | 3.59 (1.31-9.81) | 0.013 |
| Preterm premature rupture of membranes | 3.51 (0.89-13.83) | 0.072 |
| Pre-eclampsia | 2.44 (0.58-10.24) | 0.222 |
| Use of aspirin | - | >0.99 |

Table 4. Maternal outcomes of patients with placental abruption and controls

| Maternal outcome | Patients with placental abruption (n=86)* | Controls (n=86)* | p Value |
|--|--|------------------|---------|
| Mode of delivery | | | |
| Caesarean section | 79 (91.9) | 20 (23.3) | <0.001 |
| Normal vaginal delivery | 3 (3.5) | 63 (73.3) | <0.001 |
| Assisted vaginal delivery | 4 (4.7) | 3 (3.5) | >0.99 |
| Caesarean section for non-reassuring fetal heart rate | 29 (33.7) | 6 (7.0) | <0.001 |
| Blood loss, ml | 700 (700) | 200 (213) | <0.001 |
| Postpartum haemorrhage of ≥ 500 ml | 54 (62.8) | 13 (15.1) | <0.001 |
| Postpartum haemorrhage of ≥ 1000 ml | 27 (31.4) | 3 (3.5) | <0.001 |
| Uterine atony | 27 (31.4) | 3 (3.5) | <0.001 |
| Need for secondary intervention for postpartum haemorrhage | 5 (5.8) [†] | 0 | 0.059 |
| Need for blood transfusion | 22 (25.6) | 3 (3.5) | <0.001 |
| Hysterectomy | 1 (1.2) | 0 | >0.99 |
| Need for relaparotomy | 0 | 0 | - |
| Transfer to intensive care unit | 4 (4.7) | 0 | 0.121 |
| Disseminated intravascular coagulation | 6 (7.0) | 0 | 0.029 |
| Death | 0 | 0 | - |
| Length of maternal hospital stay, d | 4 (2) | 3 (2) | <0.001 |
| Prolonged maternal hospitalisation of >4 d | 26 (30.2) | 13 (15.1) | 0.018 |

* Data are presented as No. (%) of participants or median (interquartile range)

[†] Compression sutures (n=4) and bilateral uterine artery ligation (n=1)

and secondary intervention (25.0% vs 1.6%, $p=0.005$) [Table 6]. Compared with neonates born from patients without a Couvelaire uterus, neonates born from patients with a Couvelaire uterus had higher rates of acidosis (umbilical cord blood pH <7.1) [53.3% vs 5.8%, $p<0.001$], lower Apgar score at 1 minute (25.0% vs 4.8%, $p=0.028$), and hypoxic-ischaemic encephalopathy (12.5% vs 0%, $p=0.039$) [Table 6].

Discussion

The worldwide incidence of placental abruption is 0.3% to 1%¹¹; the incidence in our cohort was 0.37%. Having a previous placental abruption is the biggest risk factor, with 10- to 15-fold higher recurrence risk¹².

Recurrent placental abruption is associated with earlier gestational age at delivery, compared with first episodes, although perinatal mortality rates are similar¹³. In our cohort, the incidence of recurrence was 17.6%, but the number of patients with subsequent pregnancies was only 15.

Other risk factors for placental abruption include pre-eclampsia (5-fold increased risk¹⁴), fetal growth restriction, non-vertex presentations, polyhydramnios, advanced maternal age, multiparity, low body mass index, pregnancy following assisted reproductive techniques, intrauterine infection, preterm prelabour rupture of membranes, abdominal trauma, smoking and drug misuse

Table 5. Perinatal and neonatal outcomes of patients with placental abruption and controls

| | Patients with placental abruption (n=89)* | Controls (n=86)* | p Value |
|---|---|------------------|---------|
| Perinatal outcome | | | |
| Gestational age at birth, wk | 35 (7) | 39 (2) | <0.001 |
| Birth before 37 weeks | 57 (64.0) | 8 (9.3) | <0.001 |
| Birth before 34 weeks | 33 (37.1) | 2 (2.3) | <0.001 |
| Birth before 28 weeks | 10 (11.2) | 0 | 0.002 |
| Livebirth | 85 (95.5) | 86 (100) | 0.121 |
| Stillbirth | 1 (1.1) | 0 | >0.99 |
| Early neonatal death | 3 (3.4) | 0 | 0.246 |
| Male sex | 52 (58.4) | 39 (45.3) | 0.083 |
| Birth weight, g | 2296.4±835.7 | 3088.8±469.6 | <0.001 |
| Birth weight <10 centile | 9 (10.1) | 13 (15.1) | 0.318 |
| Neonatal outcome | | | |
| Apgar score at 1 min | 7 (3) | 8 (0) | <0.001 |
| Apgar score at 1 min <4 | 7 (7.9) | 0 | 0.014 |
| Apgar score at 5 min | 9 (2) | 9 (0) | 0.055 |
| Apgar score at 5 min <7 | 7 (7.9) | 1 (1.2) | 0.064 |
| Umbilical artery pH <7.1 | 11/73 (15.1) | - | - |
| Resuscitation at birth | 16 (18.2) | 0 | <0.001 |
| Mechanical ventilation | 22 (25.0) | 1 (1.2) | <0.001 |
| Admission to neonatal intensive care unit | 42 (47.7) | 1 (1.2) | <0.001 |
| Haemodynamic instability required inotropes | 11 (12.5) | 0 | 0.001 |
| Need for blood transfusion | 15 (17.0) | 0 | <0.001 |
| Respiratory distress syndrome | 35 (39.8) | 0 | <0.001 |
| Apnoea of prematurity | 22 (25.0) | 0 | <0.001 |
| Transient tachypnoea of the newborn | 7 (8.0) | 3 (3.5) | 0.330 |
| Intraventricular haemorrhage | 7 (8.0) | 0 | 0.014 |
| Hypoxic-ischaemic encephalopathy | 2 (2.3) | 0 | 0.497 |
| Necrotising enterocolitis | 3 (3.4) | 0 | 0.246 |
| Chronic lung disease | 7 (8.0) | 0 | 0.014 |
| Retinopathy of prematurity | 7 (8.0) | 0 | 0.014 |
| Patent ductus arteriosus | 11 (12.5) | 0 | 0.001 |
| Hypoglycaemia | 12 (13.6) | 3 (3.5) | 0.017 |
| Jaundice-required phototherapy | 21 (23.9) | 18 (20.9) | 0.643 |
| Sepsis | 10 (11.4) | 2 (2.3) | 0.019 |
| Epilepsy | 2 (2.3) | 1 (1.2) | >0.99 |
| Cerebral palsy | 2 (2.3) | 0 | 0.497 |
| Length of hospital stay, d | 7 (32) | 2 (2) | <0.001 |
| Early death | 3 (3.4) | 0 | 0.246 |

* Data are presented as mean ± standard deviation, median (interquartile range), or No. (%) of participants

Table 6. Adverse maternal and neonatal outcomes in patients with placental abruption with or without a Couvelaire uterus

| | % of patients | | p Value |
|---|--|---|---------|
| | Patients with Couvelaire uterus (n=16) | Patients without Couvelaire uterus (n=63) | |
| Adverse maternal outcomes | | | |
| Uterine atony | 56.3 | 27.0 | 0.026 |
| Disseminated intravascular coagulation | 25.0 | 3.2 | 0.014 |
| Postpartum haemorrhage | 93.8 | 61.9 | 0.014 |
| Blood transfusion | 68.8 | 17.5 | <0.001 |
| Secondary intervention | 25.0 | 1.6 | 0.005 |
| Admission to intensive care unit | 6.3 | 4.8 | >0.99 |
| Adverse neonatal outcomes | | | |
| Birth before 28 weeks | 18.8 | 7.9 | 0.348 |
| Early neonatal death | 6.3 | 1.6 | 0.366 |
| Umbilical cord blood pH <7.1 | 53.3 | 5.8 | <0.001 |
| 1-minute Apgar score <4 | 25.0 | 4.8 | 0.028 |
| 5-minute Apgar score <7 | 18.8 | 6.3 | 0.143 |
| Resuscitation at birth | 31.3 | 15.9 | 0.171 |
| Admission to neonatal intensive care unit | 62.5 | 44.4 | 0.197 |
| Hypoxic-ischaemic encephalopathy | 12.5 | 0 | 0.039 |
| Cerebral palsy | 6.3 | 1.6 | 0.366 |
| Epilepsy | 6.3 | 1.6 | 0.366 |

(cocaine and amphetamines) during pregnancy¹⁵. In our cohort, other risk factors for placental abruption were pre-eclampsia, preterm prelabour rupture of membranes, antepartum haemorrhage, and the use of antenatal aspirin, but these became not significant after adjusting for confounders, except for a history of antepartum haemorrhage.

In a systematic review, patients with chronic hypertension with superimposed pre-eclampsia have 2.8-7.7-fold increased risk of placental abruption¹⁶. Severe pre-eclampsia is a strong risk factor for placental abruption, whereas transient hypertension in pregnancy and mild pre-eclampsia are associated with placental abruption. The common aetiology of placental abruption and pre-eclampsia is related to failed placentation in early pregnancy, which may lead to placental dysfunction and further increased risk of abruption. Among patients with preterm prelabour rupture of membranes, the incidence of placental abruption is 4% to 12%¹⁶. The association is due to either a sudden reduction of uterine volume or an ascending intrauterine infection.

Among patients who used antenatal low-dose

aspirin, nine (10.5%) had placental abruption. In a meta-analysis, prophylactic low-dose aspirin (<100 mg per day) has no effect on the risk of placental abruption or antepartum haemorrhage, irrespective of the gestational age at onset of therapy¹⁷. However, when the dose is ≥ 100 mg per day, the risk of placental abruption is lower in women who started treatment before 16 weeks than after 16 weeks. Placental abruption and preeclampsia are due to impaired placentation; aspirin administration for women with an increased risk of impaired placentation may reduce the risk of placental abruption, as it does for preeclampsia. The ASPRE trial recommends that a daily dose of ≥ 100 mg before 16 weeks of gestation is effective in reducing the risk of preeclampsia¹⁸. However, the risk of placental abruption or antepartum haemorrhage may increase without reducing the risk of preeclampsia if treatment is started after 16 weeks of gestation, because placentation is mostly complete by 18 weeks of gestation. In patients with persistent abnormal placentation, the use of aspirin (through its antiplatelet properties) can increase the risk of haemorrhage and placental abruption. In our patients, all were on 80 mg aspirin daily started before 16 weeks, and antenatal aspirin use was not found to be a risk factor.

Smoking and drug abuse is a risk factor for placental abruption but was not significant in our study, probably owing to the small sample size and confounding factors. Of 172 patients in our study, only nine were smokers and only two were drug abusers, whereas only one had polyhydramnios and only one had abdominal trauma.

There are no universal diagnostic criteria for placental abruption. The most common clinical presentation leading to the diagnosis of placental abruption is the presence of retroplacental clot/haemorrhage during delivery¹⁹. 96.5% of our patients with placental abruption had this clinical presentation.

Ultrasound is useful to rule out other causes of antepartum haemorrhage and abdominal pain such as placenta previa and adnexal masses. It is useful in diagnosing retroplacental haematomas, with a positive predictive value of 88% and a sensitivity of 25% to 60%, as it is absent in




Figure 1. An ultrasound scan showing a retroplacental hematoma (outlined by arrows).

many patients with placental abruption²⁰⁻²³. It is difficult to differentiate a concealed haemorrhage of the surrounding placental tissue during the acute phase of placental abruption, as the blood may be isoechoic. The locations of placental abruption can be subchorionic, retroplacental, and preplacental. Retroplacental haematomas with variable appearance is a common ultrasound finding (Figure 1). They may appear to be solid, complex, hypo-, hyper- or iso-echoic, compared with the placenta, depending on the severity and timing of the abruption. The absence of a positive ultrasound finding does not exclude the diagnosis of abruption.

Placental abruption may lead to emergency caesarean birth for fetal or maternal indications, excessive blood loss, and disseminated intravascular coagulation, which can lead to hypovolaemic shock, acute kidney injury, multiorgan failure, respiratory distress syndrome, peripartum hysterectomy, and death^{16,24}. In our study, placental abruption was associated with higher rates of caesarean sections, postpartum haemorrhage, uterine atony, blood transfusion, and disseminated intravascular coagulation.

16 of our patients with placental abruption were found to have a Couvelaire uterus intraoperatively (Figure 2), which occurs when a ruptured decidual spiral artery causing bleedings into the decidua basalis and the myometrium during a severe placental abruption. As blood permeates into the uterine serous layer, a blue-violet ecchymosis occurs²⁵. The Couvelaire uterus is atonic and very prone to postpartum haemorrhage and thus aggressive and timely management of atony may prevent further worsening of conditions such as disseminated intravascular coagulation and exsanguination. Uterine atony in a



Figure 2. Intra-operative finding of Couvelaire uterus in two patients.

Couvellaire uterus responds less well to standard treatments and is at high risk of hysterectomy. In our patients with a Couvellaire uterus, the rates of uterine atony, postpartum haemorrhage, disseminated intravascular coagulation, and blood transfusion were all higher. Of the five patients who underwent secondary intervention, three of the four patients with compression sutures were those with a Couvellaire uterus. Therefore, it is crucial for surgeons to anticipate the risk of worsened outcomes when a Couvellaire uterus is noted intraoperatively and be proactive in the prevention of deterioration. The more severe the placental abruption, the worse the neonatal outcome.

In our study, there was no maternal death. This may be due to the timely diagnosis and prompt treatment of postpartum haemorrhage by a multidisciplinary team. High vigilance towards uterine atony and postpartum haemorrhage and timely involvement of other specialties (neonatologists, intensivists, anaesthesiologists, and haematologists) and massive transfusion protocol for expeditious transfusion and support are important.

Adverse perinatal outcomes of pregnancies complicated with placental abruption include low Apgar score, preterm birth, lower birth weight, and perinatal mortality^{2,11,26-34}. 64% of our patients with placental abruption were delivered prematurely. The risk of preterm birth may be related to preterm labour or preterm prelabour rupture of membranes or a non-reassuring fetal or maternal condition. Neonatal morbidities are associated with both complications of placental abruption and prematurity². In our cohort, neonates born from patients with placental abruption had an increased (but not significantly) risk of acidosis (15%) and cerebral palsy and hypoxic ischaemic encephalopathy. These problems are more likely to be attributable to the acute event of placental abruption leading to perinatal asphyxia than prematurity.

Limitations of the present study include the retrospective nature and the small sample size. The incidence of placental abruption may be underestimated, as antepartum haemorrhage of unknown origin can be marginal bleeding of the placenta, which may be a type of very minor abruption that was not included. 64% of

neonates born from patients with placental abruption were preterm, and the neonatal outcome was not controlled for gestation at delivery. Thus, the placental abruption group had higher neonatal morbidities that could be associated with prematurity (rather than placental abruption alone).

Conclusion

Clinicians should be vigilant for placental abruption in patients with antepartum haemorrhage, especially in high-risk patients with a history of placental abruption, hypertension, or pre-eclampsia. Early and consistent antenatal care is imperative to identify those with risk factors. Proper education and timely preventive management should be provided to improve maternal and fetal outcomes.

Contributors

All authors designed the study, acquired the data, analysed the data, drafted the manuscript, and critically revised the manuscript for important intellectual content. All authors had full access to the data, contributed to the study, approved the final version for publication, and take responsibility for its accuracy and integrity.

Conflicts of interest

All authors have disclosed no conflicts of interest.

Funding/support

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Data availability

All data generated or analysed during the present study are available from the corresponding author upon reasonable request.

Ethics approval

The study was approved by the New Territories West Research Ethics Committee (reference: NTWC/REC/22071). The patients were treated in accordance with the tenets of the Declaration of Helsinki. The patients provided written informed consent for all treatments and procedures and for publication.

References

1. Maeland KS, Morken NH, Schytt E, Aasheim V, Nilsen RM. Placental abruption in immigrant women in Norway: a population-based study. *Acta Obstet Gynecol Scand* 2021;100:658-65. [Crossref](#)

2. Lueth A, Blue N, Silver RM, et al. Prospective evaluation of placental abruption in nulliparous women. *J Matern Fetal Neonatal Med* 2022;35:8603-10. [Crossref](#)
3. Sheiner E. *Textbook of Perinatal Epidemiology*. Nova Science; 2010.
4. Gaufer SA. Abruptio placentae from emergency medicine/obstetrics and gynaecology. *e-Med J* 2001;2(3).
5. Bonnar J. Massive obstetric haemorrhage. *Baillieres Best Pract Res Clin Obstet Gynaecol* 2000;14:1-18. [Crossref](#)
6. Spinillo A, Fazzi E, Stronati M, Ometto A, Laschi A, Guaschino S. Severity of abruptio placentae and neurodevelopmental outcome in low birth weight infants. *Early Hum Dev* 1993;35:45-54. [Crossref](#)
7. Ananth CV, Oyelese Y, Yeo L, Pradhan A, Vintzileos AM. Placental abruption in the United States, 1979 through 2001: temporal trends and potential determinants. *Am J Obstet Gynecol* 2005;192:191-8. [Crossref](#)
8. Ananth CV, Smulian JC, Demissie K, Vintzileos AM, Knuppel RA. Placental abruption among singleton and twin births in the United States: risk factor profiles. *Am J Epidemiol* 2001;153:771-8. [Crossref](#)
9. Jenabi E, Ebrahimzadeh Zagami S. The association between uterine leiomyoma and placenta abruption: a meta-analysis. *J Matern Fetal Neonatal Med* 2017;30:2742-6. [Crossref](#)
10. Panagiotopoulos M, Tseke P, Michala L. Obstetric complications in women with congenital uterine anomalies according to the 2013 European Society of Human Reproduction and Embryology and the European Society for Gynaecological Endoscopy Classification: a systematic review and meta-analysis. *Obstet Gynecol* 2022;139:138-48. [Crossref](#)
11. Sheiner E, Shoham-Vardi I, Hadar A, Hallak M, Hackmon R, Mazor M. Incidence, obstetric risk factors and pregnancy outcome of preterm placental abruption: a retrospective analysis. *J Matern Fetal Neonatal Med* 2002;11:34-9. [Crossref](#)
12. Ananth CV, Savitz DA, Williams MA. Placental abruption and its association with hypertension and prolonged rupture of membranes: a methodologic review and meta-analysis. *Obstet Gynecol* 1996;88:309-18. [Crossref](#)
13. Kojima T, Takami M, Shindo R, Saigusa Y, Miyagi E, Aoki S. Perinatal outcomes of recurrent placental abruption. *J Matern Fetal Neonatal Med* 2021;34:2192-6. [Crossref](#)
14. Bellos I, Pergialiotis V, Papapanagiotou A, Loutradis D, Daskalakis G. Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network meta-analysis. *Am J Obstet Gynecol* 2020;223:525-37. [Crossref](#)
15. Ananth CV, Patrick HS, Ananth S, Zhang Y, Kostis WJ, Schuster M. Maternal cardiovascular and cerebrovascular health after placental abruption: a systematic review and meta-analysis (CHAP-SR). *Am J Epidemiol* 2021;190:2718-29. [Crossref](#)
16. Tikkanen M. Placental abruption: epidemiology, risk factors and consequences. *Acta Obstet Gynecol Scand* 2011;90:140-9. [Crossref](#)
17. Roberge S, Bujold E, Nicolaides KH. Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. *Am J Obstet Gynecol* 2018;218:483-9. [Crossref](#)
18. Roberge S, Bujold E, Nicolaides K. Aspirin for the prevention of preterm and term preeclampsia : systematic review and metaanalysis. *Am J Obstet Gynecol* 2018;218:287-93. e1. [Crossref](#)
19. Elsasser DA, Ananth CV, Prasad V, Vintzileos AM; New Jersey-Placental Abruption Study Investigators. Diagnosis of placental abruption: relationship between clinical and histopathological findings. *Eur J Obstet Gynecol Reprod Biol* 2010;148:125-30. [Crossref](#)
20. Shinde GR, Vaswani BP, Patange RP, Laddad MM, Bhosale RB. Diagnostic performance of ultrasonography for detection of abruption and its clinical correlation and maternal and foetal outcome. *J Clin Diagn Res* 2016;10:QC04-7. [Crossref](#)
21. Glantz C, Purnell L. Clinical utility of sonography in the diagnosis and treatment of placental abruption. *J Ultrasound Med* 2002;21:837-40. [Crossref](#)
22. Sholl JS. Abruptio placentae: clinical management in nonacute cases. *Am J Obstet Gynecol* 1987;156:40-51. [Crossref](#)
23. Jaffe MH, Schoen WC, Silver TM, Bowerman RA, Stuck KJ. Sonography of abruptio placentae. *AJR Am J Roentgenol* 1981;137:1049-54. [Crossref](#)
24. Oyelese Y, Ananth CV. Placental abruption. *Obstet Gynecol* 2006;108:1005-16. [Crossref](#)
25. Lee YJ, Calvert K, Jape K. Couvelaire uterus resulting in haemoperitoneum. *J Surg Case Rep* 2022;2022:rjab618. [Crossref](#)
26. Ananth CV, Berkowitz GS, Savitz DA, Lapinski RH. Placental abruption and adverse perinatal outcomes. *JAMA* 1999;282:1646-51. [Crossref](#)
27. Ananth CV, Wilcox AJ. Placental abruption and perinatal mortality in the United States. *Am J Epidemiol* 2001;153:332-7. [Crossref](#)
28. Ananth CV, Smulian JC, Srinivas N, Getahun D, Salihu HM. Risk of infant mortality among twins in relation to placental abruption: contributions of preterm birth and restricted fetal growth. *Twin Res Hum Genet* 2005;8:524-31. [Crossref](#)
29. Raymond EG, Mills JL. Placental abruption. Maternal risk factors and associated fetal conditions. *Acta Obstet Gynecol Scand* 1993;72:633-9. [Crossref](#)
30. Rasmussen S, Irgens LM, Bergsjø P, Dalaker K. Perinatal mortality and case fatality after placental abruption in Norway 1967-1991. *Acta Obstet Gynecol Scand* 1996;75:229-34. [Crossref](#)
31. Tikkanen M, Luukkaala T, Gissler M, et al. Decreasing perinatal mortality in placental abruption. *Acta Obstet Gynecol Scand* 2013;92:298-305. [Crossref](#)
32. Faiz AS, Demissie K, Rich DQ, Kruse L, Rhoads GG. Trends and risk factors of stillbirth in New Jersey 1997-2005. *J Matern Fetal Neonatal Med* 2012;25:699-705. [Crossref](#)
33. Brailovschi Y, Sheiner E, Wiznitzer A, Shahaf P, Levy A. Risk factors for intrapartum fetal death and trends over the years. *Arch Gynecol Obstet* 2012;285:323-9. [Crossref](#)
34. Downes KL, Shenassa ED, Grantz KL. Neonatal outcomes associated with placental abruption. *Am J Epidemiol* 2017;186:1319-28. [Crossref](#)